14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CAMP vs ZURA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over Zura Bio Limited Class A (ZURA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CAMP carries a Unified Composite Score of 41.9/100 (SELL) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas ZURA carries 46.3/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ZURA currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. CAMP 41.9/100 SELL), CAMP captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-991.8% vs. 0.0% operating margin) and revenue trajectory (+138.9% vs. +0.0% YoY).
Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.3); meanwhile ZURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAMP vs ZURA. Trailing 12-month operating profitability (CAMP -991.8% vs ZURA 0.0%) and valuation multiples (CAMP N/M vs ZURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $119.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CAMP vs ZURA Key Questions & Quantitative Answers
As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over Zura Bio Limited Class A (ZURA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CAMP carries a Unified Composite Score of 41.9/100 (SELL) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas ZURA carries 46.3/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ZURA currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. CAMP 41.9/100 SELL), CAMP captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-991.8% vs. 0.0% operating margin) and revenue trajectory (+138.9% vs. +0.0% YoY). Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.3); meanwhile ZURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with ZURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CAMP generates $5.3M in USD-normalized revenue versus N/A for ZURA. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZURA.
CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas ZURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus ZURA (-63.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, ZURA carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 1.51x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.55β · 272% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.